Skip to main content


Fig. 1 | Cardiovascular Diabetology

Fig. 1

From: Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice

Fig. 1

Serum lipid and fasting blood glucose levels in Cana- and control-groups after 5 weeks of canagliflozin/vehicle oral administration. Significant reduction in total cholesterol, triglyceride, LDL-cholesterol and fasting blood glucose levels was observed in Cana-group at the end of experimental procedure compared to baseline. Fasting glucose was the only significantly increased parameter observed in the control group at the end of intervention. Data are shown as mean ± SD (***P ≤ 0.001, **P ≤ 0.01)

Back to article page